Code of Conduct
Our Code of Conduct sets the ethical standards that guides all our business activities. It´s about all of us. Each individual plays a vital role in bringing the Code of Conduct to live.
Search
The little things
In 2009 Anna was diagnosed with scleroderma. For her, however, the disease is no reason to give up. On the contrary.
Harold and Dorothy – Full Story
T2D and CVD animation the full story – learn about the relationship between type 2 diabetes and cardiovascular disease
It’s Your Heart. Protect It. The Podcast.
In season 2, we hear from a range of experts to explore further how the interconnected systems call for collaboration and approach to care.
Our products for COPD
Our products for COPD
Local healthcare community raise alarm bells on growing trend of cardiovascular disease risk
Local healthcare community raise alarm bells on growing trend of cardiovascular disease risk factors associated with type 2 diabetes
Cairo Tower lights up in Blue for World Diabetes Day
Cairo Tower lights up in Blue for World Diabetes Day
Boehringer Ingelheim Opens New Scientific Office in Kenya as Part of its Commitment to Improve Human and Animal Health in Africa
Boehringer Ingelheim has officially opened its new scientific office in Nairobi, Kenya.
Boehringer Ingelheim Raises Ranking by Two Positions in Access-To-Medicine Index for 2021
Boehringer Ingelheim Raises Ranking by Two Positions in Access-To-Medicine Index for 2021
Trust Through Transparency
Our Innovation Strategy
Our discovery research strategy is designed to sustain our track record of innovation and look for new and breakthrough medicines.
Respiratory Diseases
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in respiratory diseases.
Innovation Prize Winners
Find out more about the winners of our Innovation Prize in Boston, New York and San Diego in the USA; Tokyo Japan and Vienna, Austria
Research in Diabetic Macular Ischemia
There are no available treatments for DMI. Scientists at Boehringer Ingelheim are working hard to change this.
Guardians for health
A global initiative to reduce mortality, cardiovascular and kidney complications in type 2 diabetes through adherence to clinical guidelines.
World Heart Day 2021
Cardiovascular diseases, including heart disease, are the leading cause of death and disability worldwide and are closely linked to kidney and metabolic diseases.
Facts about the INPULSIS™ trials
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
In 2023, Boehringer Ingelheim in India, Middle East, Turkey and Africa (IMETA) region achieved net sales of EUR 779 million, reflecting a 13% increase compared to the previous year.
Ofev®
Ofev® is a prescription medication used to treat people with idiopathic pulmonary fibrosis (IPF) systemic sclerosis-associated interstitial lung disease (SSc-ILD) and other chronic fibrosing interstitial lung diseases with a progressive phenotype
Stroke Risk Factors Symptoms
Suffering a stroke is one of the most devastating medical emergencies that can happen to a person. There is a simple test that can help everyone identify the most common symptoms of a stroke.
Focus on Alliance Management
Stefan Walke, Global Head of Alliance Management, shares his perspectives on Alliance Management and its contribution to the development of successful long-term partnerships.
Boehringer Ingelheim appoints new Regional Managing Director
Boehringer Ingelheim appoints new Regional Managing Director
Protein Degraders in Cancer
Boehringer Ingelheim scientists and their partners are exploring how protein degraders could bring so-called undruggable cancer targets within reach
Pulmonary Fibrosis Awareness Month 2020
Hear what Peter Fang said about pulmonary fibrosis awareness month, our commitment to advancing care and our engaging new campaign, ‘the most important postcard you will ever write’
The Bigger Picture of Treatment Sequencing
The Bigger Picture of Treatment Sequencing